Navigation Links
Cyberonics Announces Epilepsy Technology Collaborations
Date:10/2/2009

ion if those facts change or if we no longer believe the assumptions to be reasonable. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning building on our position as the leader in medical devices for epilepsy, accelerating our program for development of an implantable pulse generator for stimulating the vagus nerve in response to EEG-based detection of a seizure, incorporating new and promising technology into future generations of the VNS Therapy System, enhancing seizure reduction and improvements to quality of life through the investments described in this press release, making other investments in research and development, and developing seizure detection for patients with epilepsy. Our actual results may differ materially. Important factors that may cause actual results to differ include, but are not limited to: continued market acceptance of VNS Therapy(TM) and sales of our product; the development and satisfactory completion of clinical trials and/or market test and/or regulatory approval of VNS Therapy(TM) for the treatment of other indications; satisfactory completion of post-market studies required by the U.S. Food and Drug Administration as a condition of approval for the treatment-resistant depression indication; adverse changes in coverage or reimbursement amounts by third-parties; intellectual property protection and potential infringement claims; maintaining compliance with government regulations and obtaining necessary government approvals for new indications; product liability claims and potential litigation; reliance on single suppliers and manufacturers for certain components; the accuracy of management's estimates of future expenses and sales; the results of the previously disclosed governmental inquiries; the potential identification of material weaknesses in our internal controls over financial reporting; risks and costs associated with such governmental inquir
'/>"/>
SOURCE Cyberonics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cyberonics to Present at Maxim Group Growth Conference
2. Cyberonics to Present at UBS Global Life Sciences Conference
3. Cyberonics Reports Strong Fiscal 2010 First Quarter Results
4. Cyberonics to Present at Canaccord Adams 29th Annual Global Growth Conference
5. Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 First Quarter Financial Results
6. Cyberonics Announces Exclusive Distribution Agreement With Nihon Kohden in Japan
7. Cyberonics Names Bryan D. Olin, Ph.D. Vice President, Quality
8. Cyberonics Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2009 Financial Results
9. Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter
10. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Third Quarter Financial Results
11. Cyberonics Names Milton M. Morris, Ph.D. Vice President, Research & Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 Although there are only 24 hours ... many people who have trouble finding time within their busy schedules ... for long periods of time to get in shape. Here are ... on the go. , Change Up Your Commute , Consider ... to add some exercise into your daily routine. If you must ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... length may be showing a genetic propensity for obesity as ... have been linked to increased body fat, but the same ... muscle, the researchers said. At 1 year, kids with ... and 3, however, these genes were linked to excessive weight ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... A crucial part of conventional in vitro fertilization (IVF) -- ... instead take place in a device inside the vagina, new ... contend that the device, called an INVOcell, might sharply cut ... also make the technology more accessible to those who don,t ...
(Date:10/20/2014)... The newly updated Worldwide Medical Market Forecasts ... facts, figures and forecasts on the global medical markets. ... categories the Worldwide Medical Market Forecasts to 2019 ... on the worldwide medical market to reveal key insights ... data for 2010-2019, covering each country market individually, allowing ...
(Date:10/20/2014)... October 20, 2014 ASCNYC (ascnyc.org) ... that helps New Yorkers living with HIV/AIDS and ... health, housing, recovery and self-sufficiency. Each year, ASCNYC ... local community through their tireless efforts. , ... Shapses , has been selected as this year’s ...
Breaking Medicine News(10 mins):Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3
... the same doctor during their first six months of ... screenings -- for lead poisoning, anemia and tuberculosis -- ... repeatedly by the same physician, often referred to as ... the children they studied. , Researchers from The Children,s ...
... Corporation of,North America, its U.S. subsidiary, MGI PHARMA, ... U.S. Food and Drug Administration,(FDA) has approved Aloxi(R) ... and vomiting (PONV) for up to 24 hours,following ... demonstrated., Aloxi, available in the United States ...
... the cause of a Hutchinson-Gilford Progeria Syndrome (HGPS), a ... to researchers at the National Cancer Institute (NCI), part ... findings, the first to indicate a biological basis for ... may also provide new insights into the biological mechanisms ...
... WATERBURY, Conn., March 2 Therap Services announces the,release ... and reporting applications. Therap version 7.2 will feature,new forms ... the Health,Tracking module and the Emergency Medical/Behavior Intervention Strategies,(EMBIS) ... in version 7.2 include: -- Behavior Plan and ...
... mirrors growth of disease, study says , , FRIDAY, Feb. ... between rising rates of carbohydrate intake and obesity and ... United States, a new study says. , Researchers noted ... 1973 to 2.1 million in 2001, which closely mirrors ...
... treatment and alcohol, drug use , , SATURDAY, March 1 ... for attention deficit-hyperactivity disorder (ADHD) might have one less thing ... kids are no more likely than their peers to abuse ... which was funded by the National Institutes of Health, is ...
Cached Medicine News:Health News:In early childhood, continuous care by 1 doctor improves delivery of health screenings 2Health News:FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting 2Health News:FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting 3Health News:FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting 4Health News:FDA Approves Aloxi(R) (Palonosetron HCL) Injection for Prevention of Postoperative Nausea and Vomiting 5Health News:Adult stem cell changes underlie rare genetic disease associated with accelerated aging 2Health News:Therap Services Announces Release 7.2 for the Developmental Disability Community 2Health News:Therap Services Announces Release 7.2 for the Developmental Disability Community 3Health News:ADHD Drugs Won't Raise Risk of Substance Abuse 2Health News:ADHD Drugs Won't Raise Risk of Substance Abuse 3
(Date:10/22/2014)... YARDLEY, Pa. , Oct. 22, 2014 /PRNewswire/ ... of their animal health medications, a Global Pharmaceutical ... and Antares serialization technology and turnkey solution to ... Photo - http://photos.prnewswire.com/prnh/20141021/153438 ... The product that was serialized and aggregated by ...
(Date:10/22/2014)... ST. LOUIS , Oct. 21, 2014 /PRNewswire-USNewswire/ ... are often subtle or unnoticed, but new technology, ... patient outcomes and leading to earlier detection of ... now affects 29 million Americans. If left untreated, ... or even blindness. Recently, optometric ...
(Date:10/22/2014)... , Oct. 22, 2014   Surefire Medical ... infusion systems designed to maximize targeted delivery of embolization ... to announce that oncologist John R. Daniels , ... Cancer Center, and surgical oncologist Steven C. Katz ... joined the Company,s Scientific Advisory Board (SAB).    ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
... Science, public health, and regulatory highlights for this ... in this document is designed for credentialed journalists. Release ... June 6, 2011. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... not contain any regulatory or enforcement actions due to ...
... – Regulus Therapeutics Inc ., a biopharmaceutical company ... microRNAs, today announced publication in the ... in mice on the antagonism of microRNA-33 (miR-33). The ... demonstrated that antagonism of miR-33 with ...
Cached Medicine Technology:FDA News & Notes - Week of June 6, 2011 2Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33 2Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33 3Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33 4Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33 5Regulus Therapeutics and Collaborators from NYU Langone Medical Center Publish New Data Demonstrating Clearance of Cholesterol from Bloodstream and Reduction of Atherosclerotic Plaques through Inhibition of microRNA-33 6
PEACOCK from NOMOS is a complete treatment,planning and delivery system exclusively designed,to support intensity modulated radiation therapy,(IMRT). PEACOCK is comprised of two breakthrough,...
... Novalis, BrainLAB's dedicated system ... and radiotherapy (SRS/SRT), represents ... precise treatments of brain ... & neck tumors, arteriovenous ...
... Oncor brings together Siemens existing patented ... MLC, and Virtual Wedge, with the ... workflow, patient position offset determination, and ... provide maximum efficiency of treatment delivery ...
Clinac Platinum Plus accelerators offer all the high performance features of the EX series and come with the latest high-precision dose sculpting technology for advanced tumor control....
Medicine Products: